Loading…
Context Therapeutics Inc. is projected to decline to $0.5105 by 2027, a -16% move from its current price of $0.6041. CNTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.577 | $0.604 | $0.6322 | -0.02% |
| Aug 6 | $0.5661 | $0.6039 | $0.6442 | -0.03% |
| Aug 7 | $0.5579 | $0.6038 | $0.6535 | -0.05% |
| Aug 8 | $0.551 | $0.6037 | $0.6614 | -0.07% |
| Aug 9 | $0.545 | $0.6036 | $0.6684 | -0.09% |
| Aug 10 | $0.5396 | $0.6035 | $0.6749 | -0.10% |
| Aug 11 | $0.5347 | $0.6034 | $0.6808 | -0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5347 | $0.6034 | $0.6808 | -0.12% |
| Week 2 | $0.508 | $0.6027 | $0.7149 | -0.24% |
| Week 3 | $0.4883 | $0.6019 | $0.742 | -0.36% |
| Week 4 | $0.4722 | $0.6012 | $0.7655 | -0.48% |
| Week 5 | $0.4584 | $0.6005 | $0.7867 | -0.59% |
| Week 6 | $0.4462 | $0.5998 | $0.8062 | -0.71% |
| Week 7 | $0.4352 | $0.5991 | $0.8246 | -0.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for solid tumors. Its product candidate CTIM-76 is a Claudin 6 (CLDN6) x CD3 bispecific antibody intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc. (CNTX) is a healthcare stock with a current price of $0.60 and a market cap of $55.13M, ranking 4353 by size. The near-term price picture remains neutral with a flat start to 2026, but longer-term forecasts show potential upside through 2030 and beyond.
Near-term forecasts place CNTX around the $0.60 range in 2026, with a min of $0.554, an avg of $0.60, and a max of $0.6703 and a 0% ROI, signaling a neutral stance. The stock trades with notable volatility risks, reflected in the 100% annualized volatility figure and a 30-day price range of $0.4107 to $0.8765.
A major floor 21.9% below — a decisive break under it would weaken the trend.
The nearest floor, 8.3% below — buyers have tended to step in here.
The nearest ceiling, 15.9% above — a clean break opens room to run.
A major ceiling 426.4% above — clearing it would confirm fresh momentum.
Key CNTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CNTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6072 | Sell | $0.6057 | Sell |
| MA 10 | $0.6101 | Sell | $0.6105 | Sell |
| MA 20 | $0.6188 | Sell | $0.6641 | Sell |
| MA 50 | $1.15 | Sell | $1.05 | Sell |
| MA 100 | $1.86 | Sell | $1.43 | Sell |
| MA 200 | $1.73 | Sell | $1.56 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.18 | Neutral |
| Stoch RSI (14) | 78.57 | Neutral |
| CCI (20) | -77.45 | Neutral |
| Williams %R (14) | -79.49 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -4.92 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 20.51 | Neutral |
| TRIX (15) | -2.58 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 44.83 | Neutral |
| Momentum (10) | -0.00 | Sell |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 0.60 | Sell |
| ADX (14) | 38.45 | Sell |
| ATR (14) | 0.04 | Info |
In the last 30 days CNTX traded in a range from $0.4107 to $0.8765, with the current price at $0.60.
The RSI(14) is 30, indicating neutral to oversold momentum. The stock sits below its nearby moving averages, with SMA50 at $1.49 and SMA200 at $1.76, suggesting near-term downside bias relative to those benchmarks. Support is identified at $0.554 and resistance at $2.03, framing a conservative risk/reward setup for the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.554 | $0.6041 | $0.6957 | 0% | Neutral | |
| $0.3824 | $0.5105 | $0.7331 | -16% | Bearish | |
| $0.3343 | $0.4695 | $0.7142 | -22% | Bearish | |
| $0.3713 | $0.5444 | $0.8654 | -10% | Neutral | |
| $0.4337 | $0.6608 | $1.09 | +9% | Neutral | |
| $0.4216 | $0.6658 | $1.13 | +10% | Neutral | |
| $0.4102 | $0.67 | $1.17 | +11% | Neutral | |
| $0.3719 | $0.6272 | $1.12 | +4% | Neutral | |
| $0.3468 | $0.6033 | $1.11 | 0% | Neutral | |
| $0.3492 | $0.6261 | $1.17 | +4% | Neutral | |
| $0.4101 | $0.8478 | $1.73 | +40% | Bullish | |
| $0.7218 | $1.60 | $3.69 | +166% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.554 | $0.6041 | $0.7173 | +0.00% |
| September 2026 | $0.4793 | $0.5777 | $0.7236 | -4.36% |
| October 2026 | $0.4876 | $0.5948 | $0.7581 | +2.95% |
| November 2026 | $0.4689 | $0.5775 | $0.7465 | -2.91% |
| December 2026 | $0.4278 | $0.5315 | $0.6957 | -7.97% |
Click any year to see its month-by-month CNTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CNTX could reach as high as $0.6957, with a base case around $0.6041 and support toward $0.554 — roughly 0% from $0.6041. Price action looks broadly range-bound.
Expect CNTX to range from $0.3824 to $0.7331 through 2027. The $0.5105 average target implies a -16% move from current prices. That is -15% versus the projected 2026 average. Expect choppier, lower action through this leg of the cycle.
The CNTX price prediction for 2028 points to an average of $0.4695 (low $0.3343, high $0.7142) — a potential decline of -22% on today's $0.6041. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2029, CNTX is projected to trade between $0.3713 and $0.8654, averaging $0.5444 — a potential decline of -10% from today's $0.6041. That is up +16% on the projected 2028 average. A consolidation phase looks the most probable path here.
Context Therapeutics Inc.'s 2030 outlook centres on $0.6608, within a $0.4337 to $1.09 range. That is up +21% on the projected 2029 average. That marks a +9% change versus current levels. Price action looks broadly range-bound.
By 2031, CNTX could reach as high as $1.13, with a base case around $0.6658 and support toward $0.4216 — roughly +10% from $0.6041. A consolidation phase looks the most probable path here.
Expect CNTX to range from $0.4102 to $1.17 through 2032. The $0.67 average target implies a +11% move from current prices. That is up +1% on the projected 2031 average. Price action looks broadly range-bound.
The CNTX price prediction for 2033 points to an average of $0.6272 (low $0.3719, high $1.12) — a potential gain of +4% on today's $0.6041. A consolidation phase looks the most probable path here.
In 2034, CNTX is projected to trade between $0.3468 and $1.11, averaging $0.6033 — a potential decline of 0% from today's $0.6041. That is -4% versus the projected 2033 average. Price action looks broadly range-bound.
Context Therapeutics Inc.'s 2035 outlook centres on $0.6261, within a $0.3492 to $1.17 range. That is up +4% on the projected 2034 average. That marks a +4% change versus current levels. A consolidation phase looks the most probable path here.
By 2040, CNTX could reach as high as $1.73, with a base case around $0.8478 and support toward $0.4101 — roughly +40% from $0.6041. Momentum favours further upside here.
Expect CNTX to range from $0.7218 to $3.69 through 2050. The $1.60 average target implies a +166% move from current prices. That is up +89% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CNTX today (≈ 1,655.355074 CNTX) could be worth
$2,655.18
+$1,655.18 (+166%) by 2050 · US Dollar
Based on the average projected CNTX price of $1.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CNTXwould be worth at today's price.
$1,000 invested in CNTX on Jul 31, 2025 (≈ 1,369.862978 CNTX) would be worth
$827.53
-$172.47 (-17.2%) today · 0.83× · US Dollar
Based on a CNTX entry price of $0.73 vs. today's $0.6041.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.614 | $983.88 | -1.6% |
| 1 month ago | $0.608 | $993.59 | -0.6% |
| 3 months ago | $2.27 | $266.12 | -73.4% |
| 6 months ago | $2.37 | $254.89 | -74.5% |
| 1 year ago | $0.73 | $827.53 | -17.2% |
| All time (4.8y) ago | $5.1 | $118.45 | -88.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CNTX forecast.
Our base-case forecast reaches $1.20 around 2050.
Implied market cap at $1.20: $110.26M
The multi-year forecast shows gradual upside from today’s price. In 2030, CNTX is projected to have an avg of $0.6787 with a min of $0.4199 and a max of $1.18, delivering a 13.1% ROI and a NEUTRAL sentiment.
By 2040 the avg is $0.7832 with a max of $1.72 and a 30.5% ROI, and the sentiment shifts to BULLISH. In 2050, the avg is $1.55 with a max of $3.56 and a 158.2% ROI, remaining BULLISH. The forecast also shows bearish episodes in 2027, 2028, and 2029, before the longer-horizon gains materialize.
These projections imply an investment path that remains modest in the near term but offers meaningful upside in the distant horizon, contingent on factors that influence a clinical-stage biopharmaceutical company and its collaborations. As with all forecasts, these are estimates rather than guarantees, and actual results can differ due to a range of market and company-specific factors.
Tap a question to reveal the answer.
2030: min $0.4199, avg $0.6787, max $1.18, ROI 13.1%, sentiment NEUTRAL.
Near term (2026) shows avg $0.60 with 0% ROI and NEUTRAL sentiment. Longer term, 2040 yields avg $0.7832 with 30.5% ROI and a bullish tone, and 2050 yields avg $1.55 with 158.2% ROI and a bullish tone. Bearish years appear in 2027, 2028, and 2029.
Based on the forecast, CNTX could exceed $2 by 2050 (2050 max $3.56). Earlier years cap below $2 (2030 max $1.18; 2040 max $1.72).
Current price is $0.60 and market cap is $55.13M. It is ranked 4353.
2035: min $0.3061, avg $0.6074, max $1.21, ROI 1.2%, sentiment NEUTRAL.
Context Therapeutics Inc. Community Discussion
0Share your Context Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.